Vividion Therapeutics Expands with HQ, R&D Center
BIOTECH: Follows 2021 Acquisition by Bayer for $2B
■ By FRED GRIER
NEWS
SAN DIEGO – Vividion Therapeutics, a company that was acquired for $1.5 billion and $500 million in biobucks three years ago by Bayer, is expanding its local presence with a brand-new headquarters and research and development (R&D) center.
Aleksandra...
Read latest San Diego Business Journal online.
Online newspapers
at PressDisplay.